Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Accumulated Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Accumulated Expenses for 7 consecutive years, with $242000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 98.64% to $242000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $242000.0 through Dec 2025, down 98.64% year-over-year, with the annual reading at $242000.0 for FY2025, 98.64% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $242000.0 at Kymera Therapeutics, down from $267000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $17.8 million in Q4 2024, with the low at $18000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $5.9 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses surged 89727.78% in 2022, then plummeted 98.64% in 2025.
  • Over 5 years, Other Accumulated Expenses stood at $228000.0 in 2021, then surged by 32.89% to $303000.0 in 2022, then surged by 4883.17% to $15.1 million in 2023, then increased by 17.9% to $17.8 million in 2024, then tumbled by 98.64% to $242000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $242000.0, $267000.0, and $449000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.